Changchun High-Tech: Jinbeixin Achieves Strong Sales Since Mid-July Launch After June 2025 Approval

Deep News

2025/10/31

Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product generated over CNY 55 million in revenue during Q3 2025. The company has established a 200-member sales team and is rapidly expanding hospital and channel coverage.

For Mesia, targeting cancer-related anorexia-cachexia, promotional efforts over the past year have driven sales close to CNY 100 million in the first three quarters of 2025. The company plans to enhance promotion further, aligning with national medical insurance negotiations to boost awareness among hospitals, doctors, and patients.

Moving forward, Changchun High-Tech will focus resources on high-potential new products to diversify its business and drive growth.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1126490787"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126490787\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126490787?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126490787","market":"nz","top_or_hot":-1,"title":"Changchun High-Tech: Jinbeixin Achieves Strong Sales Since Mid-July Launch After June 2025 Approval","media":"Deep News","content":"<p>Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product generated over CNY 55 million in revenue during Q3 2025. The company has established a 200-member sales team and is rapidly expanding hospital and channel coverage.</p>\n<p>For Mesia, targeting cancer-related anorexia-cachexia, promotional efforts over the past year have driven sales close to CNY 100 million in the first three quarters of 2025. The company plans to enhance promotion further, aligning with national medical insurance negotiations to boost awareness among hospitals, doctors, and patients.</p>\n<p>Moving forward, Changchun High-Tech will focus resources on high-potential new products to diversify its business and drive growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech: Jinbeixin Achieves Strong Sales Since Mid-July Launch After June 2025 Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech: Jinbeixin Achieves Strong Sales Since Mid-July Launch After June 2025 Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time smaller\">2025-10-31 17:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product generated over CNY 55 million in revenue during Q3 2025. The company has established a 200-member sales team and is rapidly expanding hospital and channel coverage.</p>\n<p>For Mesia, targeting cancer-related anorexia-cachexia, promotional efforts over the past year have driven sales close to CNY 100 million in the first three quarters of 2025. The company plans to enhance promotion further, aligning with national medical insurance negotiations to boost awareness among hospitals, doctors, and patients.</p>\n<p>Moving forward, Changchun High-Tech will focus resources on high-potential new products to diversify its business and drive growth.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0075","symbol_name":"新三板","start_time":0,"source_url":"","article_id":"1126490787","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126490787","pubTimestamp":1761903032,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0075":"新三板","BK0188":"融资融券","BK0028":"国家队","BK0046":"生物疫苗","000661":"长春高新","BK0057":"长吉图板块","BK0239":"医药制造"},"translate_title":"长春高新：金贝芯2025年6月获批后7月中旬上市以来实现强劲销售","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91272":1,"000661":1},"content_text":"Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product generated over CNY 55 million in revenue during Q3 2025. The company has established a 200-member sales team and is rapidly expanding hospital and channel coverage.\nFor Mesia, targeting cancer-related anorexia-cachexia, promotional efforts over the past year have driven sales close to CNY 100 million in the first three quarters of 2025. The company plans to enhance promotion further, aligning with national medical insurance negotiations to boost awareness among hospitals, doctors, and patients.\nMoving forward, Changchun High-Tech will focus resources on high-potential new products to diversify its business and drive growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}